Physician profile
Jyotsna Bhatnagar
NPI 1629215272
$1,778.06
in general payments reported to CMS, 2019-2025
22 companies · $194 in 2025
The $194 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $142 · 2021: $343 · 2022: $560 · 2023: $127 · 2024: $85.26 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $326 · Education: $81.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $325.73 |
| Education | $81.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $366.84 | 2019-2023 | Farxiga |
| Travere Therapeutics, INC. | $208.02 | 2024-2025 | Filspari |
| Amgen INC. | $192.90 | 2020-2022 | |
| Fresenius USA Marketing, INC. | $180.53 | 2021-2023 | Korsuva, Velphoro |
| Vifor Pharma, INC. | $141.67 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $133.97 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $99.99 | 2021 | |
| Aurinia Pharma U.S., INC. | $90.83 | 2021-2023 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $47.26 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $45.13 | 2019-2020 | |
| Glaxosmithkline, LLC. | $42.64 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $37.83 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $29.65 | 2025 | Yorvipath |
| Takeda Pharmaceuticals U.S.A., INC. | $28.36 | 2021 | |
| Calliditas Therapeutics US INC. | $27.75 | 2025 | Tarpeyo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.25 | 2019 | |
| Daiichi Sankyo INC. | $16.92 | 2021 | |
| Medtronic, INC. | $16.90 | 2023 | Ellipsys Vascular Access System |
| Scpharmaceuticals INC. | $14.13 | 2025 | |
| Abbott Laboratories | $14.13 | 2019 | |
| Eisai INC. | $12.18 | 2021 | |
| Novo Nordisk INC | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jyotsna Bhatnagar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.